Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-101 open-label single ascending dose study in LCA10-IVS26 retinal degeneration
NL-OMON54872Phase 2Withdrawn
- Sponsor
- Editas Medicine
- Start
- Jul 2021
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EDIT-101 in Leber's congenital amaurosis type 10 (LCA10), Fundus dystrophy, sponsored by Editas Medicine. Planned start Jul 2021; status: withdrawn.
02
Drugs
EDIT-101
03
Conditions
Leber's congenital amaurosis type 10 (LCA10)Fundus dystrophy
Beyond the preview
Go deeper on NL-OMON54872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54872.